University of Patras
Η συσχέτιση ορμονικών και μεταβολικών παραγόντων με την επιθετικότητα της νόσου σε ασθενείς με κλινικά εντοπισμένο καρκίνο του προστάτη
Abstract
dc:descriptionPurpose: Prostate cancer patients are a heterogeneous group concerning the aggressiveness of the disease. The relationship of steroid hormones with the aggressiveness of prostate cancer is unclear. It is known that the Anti-Müllerian Hormone (AMH), inhibits prostate cancer cell lines in vitro. The aim of this study is to investigate the relationship of AMH and steroid hormones with the aggressiveness of prostate cancer. In addition, the precise role of metabolic syndrome in this variability of prostate cancer remains unclear. This study will investigate the relationship between metabolic factors and their potential role in predicting the aggressiveness of prostate cancer. Methods: This was a prospective study of consecutive radical prostatectomy patients. We measured the following hormones: total testosterone, sex hormone binding globulin, albumin, luteinizing hormone, follicle stimulating hormone, estradiol, dehydroepiandrosterone sulfate, androstenedione and AMH. Also, a comprehensive metabolic profile was established by measuring weight, height, body mass index, waist circumference, triglycerides, HDL and LDL cholesterol and fasting glucose, as well as noting hypertension, diabetes mellitus and metabolic syndrome. The minimum follow-up was five years after surgery. Aggressiveness of prostate cancer was assessed based on three criteria: post-operative Gleason score of 8 or higher, pT3 disease classification according to the TNM staging system, and PSA biochemical recurrence (BCR) after surgery. Results: In total, 91 patients were enrolled. The mean age and PSA was 64.8 years and 9.3 ng/dl, respectively. The median post-operative GS was 7. Low AMH blood levels were correlated with higher post-operative GS (p=0.001), as well as with PSA BCR (p=0.043). With pT3 disease, only albumin was (negatively) correlated (p=0.008). ROC analysis showed that AMH is a good predictor of BCR (AUC 0.646, 95% CI 0.510-0.782, p=0.043); a cut-off value of 3.06 ng/dl had a positive prognostic value of 71.4% and negative prognostic value of 63.3 % for BCR. Cox regression analysis showed that AMH is a statistically significant and independent prognostic marker for BCR (p=0.013). More precisely, for every 1 ng/ml of AMH rise, the probability for PSA BCR decreases by 20.8% (HR= 0.792). Moreover, in Kaplan-Meier analysis, disease-free survival is more probable in patients with AMΗ≥ 3.06 ng/ml (p=0.004).Concerning the metabolic features, the median body mass index and waist circumference was 28.3 kg/m2 and 93 cm, respectively. Almost one third (29.6%) of the participants had metabolic syndrome. Increased waist circumference was associated with larger post-operative Gleason primary grade (p=0.041), while metabolic syndrome was associated with pT3 disease (p=0.005). Kaplan-Meier analysis also revealed a correlation of metabolic syndrome and PSA biochemical recurrence after radical prostatectomy (p=0.025). Conclusion: Low AMH blood levels were correlated with aggressive prostate cancer in this radical prostatectomy cohort of patients. Therefore, AMH could be a prognostic biomarker for the aggressiveness of the disease. Furthermore, the current study observed a significant correlation between metabolic syndrome and aggressive prostate cancer characteristics within a cohort of patients undergoing radical prostatectomy. Therefore, patients with metabolic syndrome should be carefully informed and observed after surgery.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kontogiannis, Stavros
- Κοντογιάννης, Σταύρος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56712